TriSalus Life Sciences Reports Financial Obligation & Equity Sale
Ticker: TLSIW · Form: 8-K · Filed: Feb 19, 2025 · CIK: 1826667
| Field | Detail |
|---|---|
| Company | Trisalus Life Sciences, Inc. (TLSIW) |
| Form Type | 8-K |
| Filed Date | Feb 19, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-obligation, equity-sale, financial-reporting
Related Tickers: TLSI
TL;DR
TriSalus took on debt and sold stock on Feb 18th.
AI Summary
On February 18, 2025, TriSalus Life Sciences, Inc. filed an 8-K detailing two key events. First, the company entered into a direct financial obligation. Second, it reported unregistered sales of equity securities. The filing does not specify the exact dollar amounts or terms of these obligations or sales.
Why It Matters
This filing indicates TriSalus Life Sciences has taken on new debt and issued equity, which could impact its financial structure and shareholder dilution.
Risk Assessment
Risk Level: medium — The filing indicates new financial obligations and unregistered equity sales, which can introduce financial risk and potential dilution for existing shareholders.
Key Players & Entities
- TriSalus Life Sciences, Inc. (company) — Registrant
- February 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- MedTech Acquisition Corp (company) — Former company name
FAQ
What type of direct financial obligation did TriSalus Life Sciences enter into?
The filing states that TriSalus Life Sciences, Inc. entered into a direct financial obligation, but does not specify the nature or terms of this obligation.
What were the details of the unregistered sales of equity securities?
The 8-K filing indicates unregistered sales of equity securities occurred on February 18, 2025, but does not provide specific details on the number of shares, price, or purchasers.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 18, 2025.
What is the principal executive office address for TriSalus Life Sciences, Inc.?
The principal executive offices of TriSalus Life Sciences, Inc. are located at 6272 W 91st Ave, Westminster, Colorado 80031.
What was TriSalus Life Sciences, Inc. formerly known as?
TriSalus Life Sciences, Inc. was formerly known as MedTech Acquisition Corp, with a name change date of September 30, 2020.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 19, 2025 regarding TriSalus Life Sciences, Inc. (TLSIW).